A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma

This phase I/II study was conducted to determine the maximum tolerated dose (MTD), safety, and efficacy of lenalidomide plus sunitinib in metastatic renal cell carcinoma (RCC) patients. Patients with histologically confirmed, metastatic RCC were treated with 10mg/day lenalidomide plus 37.5mg/day sun...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2014-09, Vol.25 (9), p.1794-1799
Hauptverfasser:	Rini, B., Redman, B., Garcia, J.A., Burris, H.A., Li, S., Fandi, A., Beck, R., Jungnelius, U., Infante, J.R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Renal Cell - drug therapy Drug Administration Schedule Female Humans Indoles - adverse effects Indoles - therapeutic use Kidney Neoplasms - drug therapy Kidneys Lenalidomide Male Maximum Tolerated Dose Medical sciences metastatic renal cell carcinoma Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Nephrology. Urinary tract diseases Original Pharmacology. Drug treatments phase I/II Pyrroles - adverse effects Pyrroles - therapeutic use Sunitinib Thalidomide - adverse effects Thalidomide - analogs & derivatives Thalidomide - therapeutic use Treatment Outcome Tumors Tumors of the urinary system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!